Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.

Authors: Orsini, E  Calabrese, E  Maggio, R  Pasquale, A  Nanni, M  Trasarti, S  Tafuri, A  Guarini, A  Foa, R 
Citation: Orsini E, etal., Leuk Res. 2006 Jul;30(7):785-94. Epub 2006 Mar 9.
Pubmed: (View Article at PubMed) PMID:16527350
DOI: Full-text: DOI:10.1016/j.leukres.2005.11.028

Leukemic bcr-abl positive dendritic cells (DCs) are likely to be present in vivo in chronic myelogenous leukemia (CML) patients, but no data are available on their functional qualities. We analyzed the circulating BDCA-1+ myeloid DC compartment in 15 chronic phase CML patients. Phenotypic features of CML DCs were comparable with that of normal DCs, except for the CD80 and CD40 antigens, significantly under-represented in CML patients. Nonetheless, no differences were found between normal samples and leukemic DCs in the allostimulatory ability, as well as in the production of cytokines and polarization of T cell responses. CML DCs were analyzed by fluorescence in situ hybridization (FISH) and found positive for the bcr-abl translocation. However, when bcr-abl+ DCs were tested for their ability to stimulate an autologous T-cell response in vitro, we could not detect a specific recognition. We conclude that an apparently normal circulating DC compartment carrying the Ph+ chromosome can be identified in CML patients; however, these cells appear unable to trigger a protective anti-leukemic immune response in autologous T cells.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11520794
Created: 2016-08-03
Species: All species
Last Modified: 2016-08-03
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.